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Abstract
Aortic valve calcification is the most common form of valvular heart disease, but the mechanisms of calcific aortic valve
disease (CAVD) are unknown. NOTCH1 mutations are associated with aortic valve malformations and adult-onset
calcification in families with inherited disease. The Notch signaling pathway is critical for multiple cell differentiation
processes, but its role in the development of CAVD is not well understood. The aim of this study was to investigate the
molecular changes that occur with inhibition of Notch signaling in the aortic valve. Notch signaling pathway members are
expressed in adult aortic valve cusps, and examination of diseased human aortic valves revealed decreased expression of
NOTCH1 in areas of calcium deposition. To identify downstream mediators of Notch1, we examined gene expression
changes that occur with chemical inhibition of Notch signaling in rat aortic valve interstitial cells (AVICs). We found
significant downregulation of Sox9 along with several cartilage-specific genes that were direct targets of the transcription
factor, Sox9. Loss of Sox9 expression has been published to be associated with aortic valve calcification. Utilizing an in vitro
porcine aortic valve calcification model system, inhibition of Notch activity resulted in accelerated calcification while
stimulation of Notch signaling attenuated the calcific process. Finally, the addition of Sox9 was able to prevent the
calcification of porcine AVICs that occurs with Notch inhibition. In conclusion, loss of Notch signaling contributes to aortic
valve calcification via a Sox9-dependent mechanism.
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Introduction
Valvular heart disease is responsible for over 20,000 deaths each
year in the United States alone, and the aortic valve is the most
commonly affected, afflicting an estimated 2.5 percent of adults
[1,2]. Valve calcification leads to stenosis and/or regurgitation
that often requires surgical valve replacement. Calcification
manifests as clusters of nodules on the arterial aspect of the aortic
valve (fibrosa) [3]. The etiology of calcific aortic valve disease
(CAVD) is proposed to involve genetic and environmental factors,
but the molecular mechanisms underlying the process of aortic
valve calcification remain poorly understood [4–6].
In vitro model systems using aortic valvular interstitial cells
(AVICs) that display osteoblast-like characteristics have provided
major insights into the mechanistic basis of calcific valve disease
[7]. In addition to the AVICs and overlying endothelial cells,
mature adult valves contain a highly diversified and dynamic
extracellular matrix (ECM) that exhibits many structural and
regulatory characteristics of connective tissues, such as those
observed in developing cartilage, tendon and bone [8]. Several
collagens and proteoglycans characteristic of cartilage are
expressed in developing and mature valves including type II and
type IX collagen, cartilage-link protein, and aggrecan and
contribute to maintaining the structural integrity of the valve
tissue. Supporting the importance of ECM proteins in valve
function, loss of ECM organization has been shown to result in
valvular maldevelopment and disease [9,10]. A key transcriptional
regulator implicated in this process is Sox9, which is expressed in
the developing endocardial cushions and mature valves and when
deleted in mice results in valve malformation and calcification
[11–13]. However, the molecular pathways that regulate Sox9 in
valve calcification remain unknown.
Mutations in the transmembrane receptor NOTCH1 were
previously reported to be associated with bicuspid aortic valve
and CAVD in human families [14]. These findings not only
supported a central role for Notch signaling in valve formation,
but also strongly suggested a necessary role for this signaling
pathway in the maintenance of normal valve function in adults.
The evolutionarily conserved Notch family of receptors regulates a
broad spectrum of cell fate decisions and developmental processes
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activation of Notch receptors (Notch1-4) by their ligands (Jagged-1
and 2 and Delta-like-1, 3 and 4) results in two successive
proteolytic cleavages, leading to the release of Notch intracellular
domain (NICD) and its nuclear translocation. In the nucleus,
NICD functions to initiate transcription of target genes, which
include the HEY (Hes-related with YPRW motif) family of
transcriptional repressors that have been implicated in early valve
development [16]. However, the role of Notch signaling in aortic
valve maintenance and CAVD is poorly understood.
Here, we show that diseased human aortic valves have
decreased expression of the constitutively active cleaved form of
Notch1 in regions of calcification. Using an in vitro primary aortic
valve cell culture system, we demonstrate that inhibition of Notch
signaling promotes calcification and results in changes in the
expression of ECM genes, which are known direct transcriptional
targets of Sox9. We find that Notch1 regulates the expression of
Sox9 in aortic valve cells and has the ability to activate a Sox9-
dependent reporter in vitro. Lastly, we show that overexpression of
Sox9 markedly attenuates the calcification that occurs with Notch
inhibition suggesting that Notch regulates calcification of aortic
valve cells in a molecular pathway mediated by Sox9.
Methods
Ethics Statement
Research was approved by the Institutional Animal Care and
Use Committee at University of Texas Southwestern Medical
Center (Protocol No. 0754-06-03-1) and Research Institute at
Nationwide Children’s Hospital (Protocol No. AR10-00026) and
conforms to the Guide for the Care and Use of Laboratory
Animals.
Human valve studies were approved by the Institutional Review
Board at Cincinnati Children’s Hospital Medical Center and
conform to the principles outlined in the Declaration of Helsinki.
Written consent was obtained from all participants involved in this
study.
Aortic Valve Interstitial Cell Culture
Rat aortic valve cusps were harvested from adult Sprague-
Dawley rats and AVICs were cultured from explants based on
published protocols [7]. Briefly, valve leaflets were subjected to
collagenase digestion and gently scraped to expose the subendo-
thelial layer. The leaflets were then cut into microscopic pieces (1–
2m m
2) and cultured in standard Medium-199 supplemented with
15% FBS, 2 mmol/L glutamine and 100 U/ml penicillin/
streptomycin. Upon reaching 80% confluency, AVICs were
passaged using trypsin-EDTA. AVICs between passage 3 and 8
were used for experiments. Similar protocol was followed for
porcine AVIC culture using valve cusps harvested from 3-week old
piglets. For rats, euthanasia was performed using inhaled carbon
dioxide while pigs were euthanized with a commercially available
intravenous mixture of pentobarbital sodium and phenytoin
sodium (Euthasol, Virbac, USA). Notch signaling was inhibited
using a c-secretase inhibitor (Sigma Cat. # S2188 or D5942)
diluted in DMSO to a concentration of 10 mM, and calcification of
rat AVICs was induced by growth in osteogenic media which
involved supplementation of standard media with 50 mg/ml
ascorbate-2-phosphate, 10 nM dexamethasone and 10 mM b-
glycerol phosphate [17]. Culture media was changed every 48–
72 hours and cells were passaged at each time point of harvest.
Overexpression of Notch targets (Hey1 and Hey2) and Sox9 was
achieved using Amaxa Nucleofector technology (Amaxa Inc.,
USA). Briefly, 0.5–1610
6 cells were nucleofected with 5 mgo f
plasmid DNA using program T16 and incubated until harvesting
for described experiments.
In situ Hybridization
35S-labeled antisense riboprobes were synthesized with T7 RNA
polymerase (MAXIScript, Ambion) for mouse Notch1, Hey1 and
Hey2 as previously described [14]. Radioactive-section in situ
hybridization was performed on paraffin-embedded sections of
hearts from 12-week old albino mice of ICR-CD1 strain following
transcardial perfusion as previously described [18]. Non-pigment-
ed albino mice were used to avoid non-specific signals resulting
from the presence of pigmented melanocytes that inhabit the
valvuloseptal apparatus from embryonic to adult life [19].
Human Aortic Valve Tissue
Human specimens were obtained from non-syndromic adult
patients at University Hospital (Cincinnati, Ohio) who had calcific
aortic valve disease and were undergoing aortic valve replacement
(mean age = 64, range 51–82 years), and from age-matched
patients at the time of autopsy, who died of non-cardiac causes.
Patients with a history of infective endocarditis or rheumatic heart
disease were excluded. Tissue was processed and analyzed as
previously described [9]. For immunohistochemistry, serial
sections (5 mm) from human aortic valves (n=4 diseased and
n=3 control) were obtained. Antigen retrieval was performed with
0.01M Citrate buffer pH 6.0 for 30 min in a pressure cooker.
Blocking was performed with 3% hydrogen peroxide for 15 min,
and 5% normal goat serum in PBS Tween20 (0.05% PBST) to
reduce non-specific binding. Sections were then incubated with
the primary antibody specific to the Notch1 intracellular domain
(1:500 dilution) (Abcam, Cambridge, MA) or Type II Collagen,
alpha 1 (COL2A1) (Abcam, Cambridge, MA) overnight at 4uC,
washed with PBST, sequentially incubated with biotinylated
secondary antibody and avidin-biotin complex (Vector Lab
Burlingame, CA), and developed with 3,39-diaminobenzidine
(DAB Peroxidase Substrate Kit, Vector Lab Burlingame, CA).
Sections were counter-stained with haematoxylin.
Gene Expression
For microarray studies, data were RMA normalized and
pairwise comparisons (of averaged signal values) and Student’s t
test with Benjamin and Hoschberg adjustment were performed
using GeneSifter (VizX Labs, Seattle, WA). Genes with an average
fold-change $ 1.5 and an adjusted p value # 0.05 were
considered significantly differentially expressed. Gene functions
were obtained from Ingenuity Pathway Analysis (IngenuityH
Systems, www.ingenuity.com) supplemented with information
from the NCBI and Stanford SOURCE search databases. The
microarray data is available on Gene Expression Omnibus (GEO)
(Accession # GSE31668) and the microarray data is MIAME
compliant. Differential expression of a subset of genes was
confirmed by qRT-PCR using RNA isolated from untreated and
DAPT treated rat AVICs with gene-specific primers in SYBR
Green 1 reactions using Bio-Rad iQ5 Multicolor Real Time PCR
machine (Bio-Rad Laboratories). Specific primer sequences are
available on request. Fold change in expression between DMSO
and DAPT treated samples was determined relative to 18S rRNA,
n=3 per group.
In COS7 cells, Sox9 mRNA levels were measured 48 hours
after transient transfection with or without pcDNA-NICD by
qRT-PCR. For porcine aortic valves, gene expression studies were
performed using Applied Biosystems 7500 Fast Real-Time PCR
System. AVICs were cultured up to a four-week time course with
either DMSO or 10 mM DAPT in M199 media containing 0.5%
Notch1 and Calcific Aortic Valve Disease
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timepoints, cells were harvested, washed with cold PBS, and
RNA was extracted and analyzed for expression of Notch1,
Runx2, alkaline phosphatase and Sox9 (primer sequences are
available upon request). Time course experiments were performed
in triplicate and qRT-PCR was performed in triplicate and fold
change determined by standardization to 18S rRNA and results
were normalized to Week 1 levels. Representative qRT-PCR
results are shown.
Protein expression was analyzed by Western blotting. Briefly,
AVICs were rinsed with cold PBS, proteins extracted with RIPA
lysis buffer (Thermo Scientific) and solubilized in 1X SDS
Laemmli sample buffer (Bio-Rad Laboratories). Whole cell
extracts from porcine and rat AVICs (,10–15 mg) were blotted
on PVDF membranes and blocked with 5% non-fat dried milk in
PBS containing 0.5% Tween 20. Immunoblots were probed
overnight at 4uC with the following antibodies: Osteopontin
(Abcam, 1:1000), Osteonectin (BioGenex, undiluted), Notch1
intracellular domain (Cell Signaling, 1:1000), Sox9 (Abcam,
1:1000), Runx2 (1:1000), GAPDH (Santa Cruz, 1:200), and a-
tubulin (Sigma, 1:2000). Immunohistochemistry of human aortic
valves was performed using antibody specific for Notch1
intracellular domain (1:500 dilution) and counter-stained with
haematoxylin (Abcam, Cambridge, MA).
Calcium Staining of AVICs
AVICs were harvested and cultured as described above. After
transfection with Sox9 plasmid as detailed above, AVICs were
grown on glass chamber slides for six days (Lab-Tek, Rochester,
NY). Cells were washed with cold PBS and fixed with 4%
paraformaldehyde in PBS for 45 minutes at 4uC. For von Kossa
staining, the cells were washed with distilled water and exposed to
5% aqueous AgNO3 and strong light for 60 minutes at room
temperature. The cells were then exposed to 2.5% sodium
thiosulfate for 5 minutes (black=positive staining) [20]. For
Alizarin red staining, the cells were washed in distilled water
and then exposed to freshly prepared 2% Alizarin red S (pH to
4.1,4.3, Sigma) for 5 minutes (red/orange=positive staining)
[20]. Digital images were taken on a Zeiss AxioImager upright
microscope with brightfield. Calcification of AVICs was assessed
using standard protocols for Alizarin red and von Kossa staining.
Quantification was performed using Image Pro Plus software.
Luciferase Reporter Assays
COS7 cells were transiently transfected using Fugene 6 (Roche)
with 5-10ng human Sox9 and 10-100ng constitutively active
mouse NICD expression plasmids along with 200 ng of the Col2a
luciferase reporter plasmid with or without the 4X48 enhancer
and 100 ng of b-galactosidase expression plasmid [21,22].
Luciferase activity was measured 48 hours after transient trans-
fection as previously described [14]. Relative luciferase activities
were calculated after normalization for transfection efficiency
using b-galactosidase. Three independent experiments were
performed in triplicate and means and standard deviations are
shown. Statistical comparisons were performed using Student’s t-
test. P value ,0.05 was considered significant. To analyze direct
activation of mouse Sox9 promoter by NICD, the endogenous
murine Sox9 core promoter (-272 to +1bp) was cloned into
pGL3basic as a XhoI-HindIII fragment. DNA fragments
encompassing the genomic sequence 5kb upstream of the
transcription start site (tss, position +1bp) were then cloned into
the core promoter construct as MluI-XhoI fragments. Fold
activation by upstream sequences in absence and presence of
NICD (0, 100 and 300ng) was determined relative to the core
promoter activity.
Statistics
Statistical comparisons were performed using Student’s t-test,
and a p value ,0.05 was considered significant.
Results
Notch1 and Hey Expression in the Adult Mouse Aortic
Valve
Notch1 is expressed in the developing cardiac outflow tract and
aortic valve during embryogenesis [14]. We sought to determine if
Notch1 expression is maintained in the adult aortic valve.
Radioactive section in situ hybridization was performed and
demonstrated expression of Notch1 mRNA and its downstream
target genes, Hey1 and Hey2, in the aortic valve of adult mice
(Figure 1). Expression was seen in the leaflet interstitium and valve
endothelium.
Loss of NOTCH1 Localized to Areas of Calcification in
Human CAVD
Histopathology with Movat’s pentachrome stain demonstrated
heterogeneous ECM disorganization in the diseased aortic valve
when compared with controls (Figure 2). Specifically, normal
ECM trilaminar stratification (Figure 2A) was lost as evidenced by
the presence of increased and disorganized collagens and
proteoglycans in all layers (Figure 2B). Cusp thickness was
increased and variable in affected tissue. AVIC disarray was
demonstrated in all aspects of the interstitium, and clusters of
AVICs were seen in proximity to areas of early mineralization
(Figure 2C) and overt calcification (Figure 2D). Evidence of
calcification was confirmed by von Kossa and Alizarin red staining
(data not shown). These findings demonstrate that CAVD is
characterized by heterogenous disruption of ECM and AVIC
organization, suggesting molecular mechanisms that regulate
calcification processes may do so in a spatially restricted manner.
To determine the expression of NOTCH1 in humans with
CAVD, we obtained explanted valve tissue from adult patients at
the time of aortic valve replacement. Aortic stenosis was the
indication for surgery in all cases. We found a marked reduction in
active NOTCH1, as measured by an antibody specific to the
NOTCH1 intracellular domain (NICD), in regions localized to
areas of calcification, which occurs in the fibrosa layer (Figure 3D
and 3F) as compared to non-calcified fibrosa of diseased valves
(Figure 3E). Of note, overall expression of NICD was increased in
the fibrosa of diseased valves compared to the acellular fibrosa of
controls, consistent with previous studies demonstrating increased
cellularity, hyperproliferation, and increased valve cusp thickness
in aortic valve disease (Figure 3A-C, 3E) [9,23]. These findings
demonstrate that CAVD is characterized by loss of NOTCH1
expression in areas of calcification along with ECM disorganiza-
tion and VIC disarray.
Notch Signaling Regulates Expression of Valve ECM
Proteins
In order to identify the downstream mediators of Notch
signaling in the early stages of aortic valve calcification, we
applied an unbiased strategy using Affymetrix microarrays. Gene
expression was performed with mRNA harvested at day 10 from
rat AVICs treated with 10 mM of the c-secretase inhibitor, DAPT
diluted in DMSO, versus cells treated with DMSO alone, defined
as control AVICs, using a previously reported culture protocol
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disorganization and VIC disarray. Representative cross sections
from control (A) and diseased (B) aortic valve cusps (3 control and
diseased valves were examined). (C) and (D) are higher magnification
images of boxed areas in (B). (A) Normal cusps have highly organized
stratified ECM with fibrosa (F, yellow), spongiosa (S, blue), and
ventricularis (V, black). (B, C) Diseased cusps have disorganized and
dispersed ECM with increased collagens (yellow) and proteoglycans
(blue) and decreased elastic fibers (black). Aortic valve cusp thickness is
increased in diseased valves when compared to control valves (A, B).
Calcification deposits are found in diseased valves (arrows, B) along
with areas of early mineralization (arrowheads, C) and clusters of VICs
that populate the margins of overt calcification (arrow, D). In general,
the fibrosa appears expanded and calcification occurs in the arterial
aspect of the cusp. The fibrosa is oriented upward in all panels, and the
scale bars equal 500 microns in (A, B) and 250 microns in (C, D).
doi:10.1371/journal.pone.0027743.g002
Figure 3. Loss of NOTCH1 expression in proximity to calcific
nodules in human aortic valves. (A) Representative sections from
control (A,B) and diseased (C-F) aortic valve cusps. (B) is high
magnification image of boxed area in (A) and (D,E) are higher
magnification of region in (C) while image in (F) shows another
calcified aortic valve. Expression of Notch1 intracellular domain (NICD) is
found in the thickened fibrosa of diseased aortic valve (C,E) as
compared to the acellular fibrosa of control valves (A,B). However,
there is significant loss of NICD expression in cells residing adjacent to
calcific nodules (D,F). The fibrosa is oriented upward in all panels, and
scale bars equal 100 microns (B,D,E,F are at same magnification). Brown
signal represents NICD expression while nuclei are counterstained in
blue.
doi:10.1371/journal.pone.0027743.g003
Figure 1. Expression of Notch1, Hey1 and Hey2 mRNAs in adult murine aortic valves by radioactive in situ hybridization. (A) Bright
field image of transverse section of 12-week old albino mouse heart. Boxed area is shown in high magnification for (B) Notch1 sense; (C) Notch1
antisense; (D) Hey1 antisense; and (E) Hey2 antisense probes. Ao, aorta; LV, left ventricle. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0027743.g001
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to DAPT treatment was confirmed by immunoblotting prior to
performing microarray studies (Figure 4B). Comparing Notch
inhibited AVICs (DAPT-treated) versus control AVICs, there
were 515 probe sets representing ,470 genes that were
differentially expressed (Table S1). A large portion of genes that
were significantly altered are cartilage-specific genes that constitute
the highly organized ECM in developing and mature aortic valve,
including genes known to be involved in cartilage metabolism,
bone mineralization and ossification (Figure 4C) [8]. No gene
expression changes consistent with calcification were noted, likely
secondary to the inability of rat AVICs to spontaneously calcify.
The most profoundly downregulated gene, which was decreased
over 20 fold, was Col2a1 (Type II collagen, alpha-1), an early
marker of chondrocyte differentiation. Several other positive
modulators of chondrogenesis or constituents of cartilage ECM
were also downregulated including Type IX collagens, Mia/Cd-
rap (melanoma inhibitory activity or cartilage-derived retinoic acid
sensitive protein), Nov/Ccn3 (nephroblastoma overexpressed
protein), Crtl1/Hapln1 (cartilage link protein/hyaluronic acid
proteoglycan linking protein 1), Matn3 (Matrillin 3), Clip2
(cartilage intermediate layer protein 2) and Lect1/Chm-1
(leukocyte cell derived chemotaxin 1 or chondromodulin-1)
(Figure 4C). Similar to NOTCH1, the expression of COL2A1
was downregulated in areas of calcification in diseased human
aortic valves (Figure S1). The differential expression of several of
these cartilage-specific ECM genes was further validated by
quantitative real time RT-PCR (qRT-PCR) (Figure 4D), consis-
tent with our findings of ECM dysregulation in diseased human
aortic valves.
The expression of these genes was examined in rat AVICs
grown in osteogenic media, which is required because AVICs of
human and rodent origin develop cellular changes associated with
calcification only by induction with organic phosphates [17]. As
expected, osteogenic media resulted in increased expression of
osteopontin, while the cartilage-specific ECM genes showed
decreased transcript levels (Figure 4E), consistent with Notch
inhibition studies in AVICs. Taken together, these findings suggest
that loss of Notch signaling is associated with abnormal ECM gene
expression in the aortic valve.
Notch1 Regulates Sox9
Investigation of Gene Ontology databases revealed that most of
the cartilage-specific genes downregulated with DAPT treatment
were also direct transcriptional targets of Sox9, a member of the
Sox family of transcription factors that is expressed in chondro-
progenitors and chondrocytes in addition to developing and
mature valves (highlighted in blue in Figure 4C) [11,12,24,25]. To
determine if Notch1 could influence Sox9-dependent activation of
cartilage-specific genes, we utilized the mouse Col2a1 luciferase
reporter, which contains 4 tandem copies of the 48bp Col2a1
enhancer fragment (harboring Sox9 binding sites) upstream of the
Col2a1 core promoter. Co-expression of constitutively active
NICD with Sox9 resulted in synergistic activation of the luciferase
reporter when compared to NICD or Sox9 alone (Figure 5A).
Interestingly, we found that transfection of NICD alone resulted in
low levels of reporter activation and this was dependent on the
presence of the enhancer containing Sox9 binding sites (Figure 5A
and Figure S2). Since the enhancer lacks any apparent RBP-Jk
binding sites for direct activation by NICD and its coactivators, we
postulated that increased reporter activation seen with NICD and
Sox9 was partly the result of Sox9 upregulation by NICD.
Accordingly, we found a dose-dependent upregulation of Sox9
mRNA in COS7 cells with overexpression of NICD by qRT-PCR
(Figure 5B).
To determine if inhibition of Notch signaling affects expression
of Sox9 in rat AVICs, we harvested mRNA after treatment with
DAPT for 10 days. Quantitative RT-PCR demonstrated a two-
fold downregulation of Sox9 mRNA in DAPT versus untreated
cells (Figure 5C). This reduction in Sox9 was also observed at the
protein level over 21 days of treatment with DAPT (Figure 5D). In
addition to Sox9, transcript levels for Sox5 and Sox6, which are
co-expressed with Sox9 and cooperate together to activate the
Col2a1 enhancer in chondrogenic cells, were found to be
decreased in AVICs with Notch inhibition (data not shown)
[25]. Analysis of mouse Sox9 upstream regulatory region revealed
a putative RBPjk binding site (Figure S3A). However, luciferase
reporter assays in COS7 cells failed to demonstrate transactivation
upon overexpression of NICD suggesting the Notch1 regulation of
Sox9 was via an indirect mechanism (Figure S3B). These findings
support a role of Notch1 in maintenance of Sox9 expression.
Notch Signaling in the Calcification of Porcine AVICs
In order to determine the role of Notch in valve calcification, we
investigated whether members of the Notch signaling pathway
could affect the calcification process in an established porcine
AVIC calcification model system (Figure 6 and Figure S4A-C) [7].
Based on our human genetic studies identifying individuals with
CAVD and NOTCH1 haploinsufficieny, we hypothesized that
inhibition of the Notch signaling pathway would accelerate the
process of calcification in this primary culture system. Interesting-
ly, we observed that porcine AVICs, which are known to
spontaneously calcify, display a gradual downregulation of Notch1
mRNA expression in concert with decreased expression of Sox9
even without DAPT treatment, which was concomitantly
associated with increased expression of osteogenic markers, Runx2
and alkaline phosphatase (Figure 6). Treatment of AVICs with
10 mM DAPT, a chemical which blocks the release of the Notch
intracellular domain (NICD), for 21 days resulted in elevated levels
of osteopontin, a molecular marker associated with osteogenesis,
and increased expression of osteonectin, which is found with in the
early stages of calcification, when compared to untreated cells
(Figure S4D and S4E). As has been previously reported, DAPT
treatment resulted in an earlier rise in Runx2 and alkaline
phosphatase mRNA levels and along with decreased levels of Sox9
mRNA (Figure S5) [26,27]. To test if Notch signaling could inhibit
valve calcification, the downstream targets Hey1 and Hey2 were
overexpressed in porcine AVICs. We found that overexpression of
Hey1 or Hey2 resulted in a decrease in osteopontin protein
expression when compared to nucleofection of an empty vector or
a GFP control vector (Figure S4G). Interestingly, we noted that
Hey2 overexpression resulted in increased Sox9 mRNA expression
but not Hey1 (Fig. S4H). Taken together, these loss and gain-of-
function studies in a well-established cell culture model for valve
calcification support the hypothesis that Notch signaling inhibits
calcification of the aortic valve, consistent with the human genetic
association of NOTCH1 haploinsufficiency to CAVD.
Overexpression of Sox9 decreases AVIC calcification that
occurs with Notch inhibition
To determine if Sox9 was functioning in a molecular pathway
regulated by Notch signaling in aortic valve calcification, we
investigated if overexpression of Sox9 could rescue the premature
calcification that occurs with chemical inhibition of Notch
signaling using the porcine AVIC calcification model system.
Overexpression of Sox9 by nucleofection was able to severely
attenuate calcification as examined by Von Kossa and Alizarin red
Notch1 and Calcific Aortic Valve Disease
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27743Figure 4. Identification of gene expression changes with inhibition of Notch signaling in rat AVICs. (A) Schematic showing the
establishment of AVIC cultures from rat aortic valves. (B) Rat AVICs treated with DAPT demonstrate downregulation of Notch1 intracellular domain
(NICD) when compared to untreated cells (DMSO only). Protein amounts were normalized to anti-a-tubulin. (C) RNA from control and DAPT-treated
AVICs cultured for 10 days was extracted and analyzed for differential gene expression using Affymetrix Rat 230 2.0 GeneChip microarrays. Table
showing fold downregulation of cartilage-specific genes with DAPT treatment of rat AVICs. In blue, direct transcriptional targets of Sox9; (*) genes
with multiple hits. Decreased expression of cartilage-specific genes by qRT-PCR in AVICs with DAPT treatment (D) or when cultured in osteogenic
media (OM) versus standard media (SM) (E). Expression of osteopontin (Opn) mRNA was upregulated in OM. *, p value,0.05. Experiments were
performed in triplicate, and means and standard deviations are shown.
doi:10.1371/journal.pone.0027743.g004
Figure 5. Notch1 regulates Sox9 expression in vitro. (A) Relative luciferase activity in COS7 cells transfected with Col2a1 luciferase reporter
along with indicated amounts of Sox9 and Notch1 intracellular domain (NICD) expression plasmids. *, p value,0.05 comparing transfection of Sox9
or NICD with empty vector; #, p value,0.05 when comparing transfection of Sox9 and NICD with either Sox9 or NICD alone. (B) Transfection of
increasing amounts of NICD expression plasmid upregulates Sox9 mRNA in COS7 cells as quantified by qRT-PCR. (C) Following treatment with DAPT,
Sox9 mRNA was downregulated by qRT-PCR in rat AVICs after 10 days of culture. Mean and standard deviations are shown. *, p value,0.05. (D)
Immunoblot analysis showing expression of Sox9 in rat AVICs over 21 days of culture treated with DAPT or DMSO (untreated). Protein amounts were
normalized using a-tubulin antibodies. Experiments in A-C were performed in triplicate and means and standard deviations are shown. Transfected
DNA amounts are in nanograms.
doi:10.1371/journal.pone.0027743.g005
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Interestingly, porcine AVICs are known to spontaneously calcify
in cell culture and the addition of Sox9 also prevented this
unstimulated calcification. Transfection of Sox9 was confirmed by
Western blot using antibody against Sox9 (data not shown). These
studies show that loss of Sox9 is required for the accelerated
calcification found with loss of Notch signaling in AVICs.
Discussion
Mutations in NOTCH1 have been linked to CAVD in humans,
and Notch signaling is known to regulate multiple molecular
pathways during embryonic and adult life including those critical
for calcification [14,28,29]. Here, we demonstrate that Notch1
and its downstream mediators are expressed in the adult aortic
valve and loss of Notch signaling is associated with areas of
calcification in human aortic valves. Furthermore, we find that
inhibition of Notch signaling downregulates the expression of
Sox9, a key chondrogenic transcription factor that regulates the
expression of ECM genes and is required for normal valve
development, and promotes calcification in vitro. In addition,
inhibition of Notch signaling in AVICs results in significant
changes in the expression of cartilage-specific genes that comprise
the valve ECM, which is altered in human CAVD. Lastly, we
show that the addition of Sox9 can rescue the calcification that
occurs in AVICs with Notch inhibition. These findings suggest a
central role for Notch signaling in the prevention of valve
calcification by regulation of Sox9.
Valvulogenesis is a complex process that begins during the early
stages of cardiac development with the formation of endocardial
cushions as a result of endothelial to mesenchymal transformation
(EMT). Notch1 signaling is known to be critical for the
cellularization of the endocardial cushions along with TGFb,
Wnt/b-catenin, and VEGF signaling pathways [30,31]. During
the later stages of embryonic development, mesenchymal cells
diversify to give rise to distinct cell types and the highly organized
ECM that constitutes the mature cardiac valve. The transcription
factor, Sox9, guides the differentiation of mesenchymal cells into
chondrocytes by activation of genes such as collagen types II, IX
and XI, cartilage link protein and aggrecan that comprise the
characteristic cartilage ECM. Murine studies have demonstrated a
requirement for Sox9 during all stages of valvulogenesis as well as
for maintenance of adult heart valves [11–13]. Germline
inactivation of Sox9 in mice results in embryonic lethality between
embryonic day (E) 11.5 and 12.5 and hypoplastic endocardial
cushions due to a failure of EMT, a phenotype similar to Notch1-
null mice [11,12,30]. Inactivation of Sox9 at later stages of
development affects the expression of cartilage matrix-associated
markers crucial for ECM maturation and diversification. Inter-
estingly, Col2a1-cre mediated heterozygous loss of Sox9 in adult
mice leads to calcium deposition, a phenotype reminiscent of mice
and humans harboring heterozygous null mutations in NOTCH1
[13,14,26,27]. More recent studies have demonstrated the role of
retinoic acid in regulating Sox9 in the process of valve calcification
[32]. Notch signaling has previously been shown to upregulate or
downregulate Sox9 expression depending upon the cellular
context [33,34]. Consistent with this, diseased dysplastic valves
demonstrate upregulation of Sox9 expression [35], similar to what
Figure 6. Loss of Notch1 and Sox9 expression is concomitant
with increased expression of osteogenic markers in porcine
AVIC culture. (A) Notch1 and (B) Sox9 mRNA levels significantly
decrease over a 3-week time course as measured by qRT-PCR while
increasing levels of (C) Runx2 and (D) alkaline phosphatase (ALP) mRNA
were noted. Weeks of culture are noted on x-axis. Time course studies
were performed triplicate and means and standard deviations are
shown. *, p value , 0.05, when compared to week 3 levels.
doi:10.1371/journal.pone.0027743.g006
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proximity to areas of calcification is decreased, and more detailed
examination of Sox9 expression in calcified human aortic valves is
needed. Our studies in conjunction with the in vivo phenotypes
found in mice and humans with loss of Notch1 or Sox9 suggest that
Notch1 is necessary to maintain Sox9 expression in the process of
valve calcification (Figure 7N). While our data do not support
Sox9 as a direct target of Notch1, the Notch signal has been shown
to be transduced through Bmp2, which is an important mediator
of valve calcification [26]. Bmp2 has been shown to directly
regulate Sox9 in chondrogenesis and additional studies are
required to determine if a similar mechanism occurs during
CAVD [36].
Mature valves exhibit a conserved trilaminar organization with
each layer characterized by distinct ECM organization and
mechanical properties [37]. On the aortic surface of the valve is
the fibrosa layer, which is densely packed with various collagen
fibrils that provide strength and stiffness, and imparts mechanical
properties similar to bone. In contrast, the central spongiosa layer
is enriched in proteolycans, enabling a more compressible matrix
while maintaining structural integrity [8]. Several cartilage-specific
proteins including cartilage link protein, Collagen type II and XI
Figure 7. Overexpression of Sox9 rescues calcification that occurs with Notch inhibition. Porcine AVICs were cultured under four
conditions: (A,E,I) untreated, (B,F,J) DAPT-treated, (C,G,K) Sox9 overexpression, and (D,H,L) DAPT-treatment following Sox9 overexpression. Bright field
image of unstained cells (A-D), and cells stained with von Kossa (E-H) and Alizarin red (I-L) are shown. AVICs demonstrated calcification with calcific
nodules in untreated and DAPT treated cells (A, B, E, F, I, J) but no calcification or nodules were found in Sox9 or DAPT/Sox9 treated cells (C, D, G, H, K,
L). Three independent experiments were performed and representative images are shown. (M) Quantification of Alizarin red staining is shown. *, p
value,0.05. (N) Schematic showing that Notch1-dependent activation of Sox9 is required for proper expression of valve ECM proteins that are
essential for normal adult valve function. Conversely, loss of Notch1 or Sox9 results in dysregulated aortic valve ECM and CAVD.
doi:10.1371/journal.pone.0027743.g007
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rise to molecular and structural properties similar to that of
cartilage ECM. The ventricularis matrix layer composed mostly of
elastic fibers is adjacent to the direction of blood flow and enables
stretching and retraction of the leaflet during each cardiac cycle.
This highly organized trilaminar ECM composition in turn
provides the mechanical durability necessary for valve function.
Supporting this notion, diseased valves invariably depict histo-
pathological changes in ECM organization and VIC distribution
[9,23]. Disorganized ECM resulting from changes in proteogly-
can, collagen and elastic fiber content have been shown to result in
either stiff or floppy valves that lead to either stenosis or
insufficiency, respectively [38]. In our studies, downregulation of
Sox9 by Notch inhibition resulted in altered expression of multiple
valve ECM proteins including Col2a1, Col9a1, Col11a2, Cd-rap
and Crtl1 which are similar to the gene expression changes found
in mice with targeted deletion of Sox9 [12]. Additionally, enzymes
involved in collagen maturation (P4ha3, collagen prolyl 4-
hydroxylase alpha 3), proteoglycan synthesis (Has2, hyaluronan
synthase 2) and collagen and elastin cross-linking (lysyl oxidases)
also showed decreased expression along with other ECM
components, such as elastin and fibronectin (Table S1), suggesting
ECM abnormalities occur in all valve layers. Consistent with these
observations, histopathological examination of aortic valve tissue
from patients with CAVD shows ECM disorganization that results
in a stiff stenotic valve, as seen in cases of NOTCH1 haploinsuffi-
ciency.
Healthy, normal cardiac valves are avascular, and neovascu-
larization of valves is a distinct histopathological characteristic of
early valve disease and is associated with aortic valve calcification
[39]. Consistent with this, we demonstrated upregulation of
osteonectin, a molecular marker of neoangiogenisis and calcifica-
tion with inhibition of Notch signaling (Figure S3F). In addition,
an antiangiogenic factor, Lect1 (also known as Chondromodulin-
1), was significantly downregulated in AVICs along with Sox9 in
response to inhibition of Notch signaling and growth in osteogenic
media (Figure 4C-E). Lect1 is known to be regulated by Sox9
during chondrogenesis and has a demonstrated role in CAVD as
Lect1-null mice have increased neoangiogenesis, leaflet thickening
and calcium deposition of valves with aging [40,41]. Moreover,
severe downregulation of Lect1 is observed in diseased cardiac
valves [41]. Notch signaling has a well-documented function in
guided vascular patterning and therefore, may also have a role in
valvular disease by regulating neoangiogenesis [42].
Heterozygous mutations in NOTCH1 have been linked to
congenital malformations of the aortic valve along with adult-onset
calcification [14,43,44,45]. Our findings suggest that aortic valve
ECM disorganization contributes to late-onset valve calcification.
Consistent with this, bicuspid aortic valve, the most common
cardiac malformation that often progresses to aortic stenosis and
calcification has been shown to have disruption of the valvar ECM
[11]. Ultimately, further elucidation of the Notch1-Sox9 molecular
pathway and its role in the maintenance of the ECM will lead to
an improved mechanistic understanding of aortic valve calcifica-
tion and development of novel therapeutic strategies for CAVD.
Supporting Information
Figure S1 Loss of COL2A1 expression in proximity to
calcific nodules in human aortic valves. (A) Representative
sections from control (A) and diseased (B-D) aortic valve cusps. (C,
D) are high magnification images of boxed area in (B). Expression
of the alpha-1 chain of type II collagen, (COL2A1) is found in the
thickened fibrosa of diseased aortic valve (B) as compared to the
acellular fibrosa of control valves (A). However, there is significant
loss of COL2A1 expression in cells residing adjacent to calcific
nodules (C) as compared to other regions lacking nodules (D).
Scale bars equal 100 microns Brown signal represents COL2A1
expression while nuclei are counterstained in blue.
(JPG)
Figure S2 Notch1 activation of Col2a1 luciferase re-
porter requires the presence of the enhancer containing
Sox9 binding sites. (A) Relative luciferase activity in COS7 cells
transfected with luciferase reporter lacking enhancer fragment that
contains Sox9 binding sites (Col2a1-lucDEnh). Indicated amounts
of Sox9 and Notch1 intracellular domain (NICD) expression
plasmids used for transient transfection are shown.
(JPG)
Figure S3 Notch1 does not activate Sox9 upstream
regulatory sequences in vitro. (A) Schematic of mouse
Sox9 promoter region and luciferase reporter constructs generat-
ed. Mouse Sox9 core promoter (-272 to +1 bp) and 3 fragments
containing the upstream sequence were cloned in pGL3basic
luciferase reporter. *, putative RBPjk binding site; tss, transcription
start site. (B) Relative luciferase levels of various constructs in
COS7 cells with or without co-transfected NICD. All luciferase
values were normalized with respect to core promoter activity. CP,
core promoter.
(JPG)
Figure S4 Porcine aortic valve interstitial cells (AVICs)
spontaneously calcify and Notch signaling alters expres-
sion of osteogenic markers in AVICs. (A) AVIC culture
established from aortic valve leaflets dissected from 3 week old
piglets. Cultured AVICs, a phenotypically diverse population of
cells comprised of myofibroblasts, fibroblasts, and smooth muscles
cells, transdifferentiate into osteoblast-like cells and undergo
spontaneous calcification by forming calcified nodules (arrow-
heads) shown in low (B) and high (C) magnification. (D)
Myofibroblast and osteoblast-specific cell markers in porcine
AVICs harvested following 3, 10, and 21 days of culture.
Myofibroblast markers vimentin and alpha-smooth muscle actin
(a-SMA) were detectable early in culture. Increasing expression of
osteoblast markers, osteopontin and the transcriptional regulator,
Runx2, was noted after increasing days in culture. Protein
amounts are normalized using GAPDH. (E) Earlier induction of
osteopontin protein following Notch inhibition with c-secretase
inhibitor in AVICs when compared to untreated cells. Analysis of
total cell lysate at days 3, 6, 10 and 21 by immunoblotting with
anti-osteopontin antibodies. (F) Immunoblot analysis demonstrates
increased osteonectin expression with treatment of AVICs with c-
secretase inhibitor (DAPT) compared to untreated cells. Days 3,
10, 15 and 21 are shown. (G) Decreased osteopontin protein by
immunoblot with overexpression of Hey1 and Hey2 in AVICs
after 10 days of culture when compared to nucleofections with no
DNA, empty vector (pcDNA) and pmaxGFP. Protein amounts
were normalized using GAPDH. (H) Increased Sox9 mRNA levels
are found with overexpression of Hey2 but not Hey1 in pAVICs as
quantified by qRT-PCR. Experiments were performed in
triplicate and means and standard deviations are shown.
(JPG)
Figure S5 Acceleration of calcification with Notch
inhibition in porcine aortic valve interstitial cell culture
system. (A,B) Representative qRT-PCR showing higher levels of
Runx2 and alkaline phosphatase (ALP) mRNA in DAPT-treated
cells at weeks 3 and 4 as compared to control cells treated with
DMSO. (C) Downregulation of Sox9 mRNA was also found with
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PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27743DAPT-treatment at 3 and 4 weeks of culture. Interestingly, Sox9
expression decreased over the 4-week time course as the cells
calcified. Time course studies were performed twice and
representative experiment is shown. qPCR studies were performed
in duplicate and average is shown and expression levels are
normalized to week 1 levels.
(JPG)
Table S1 Gene expression changes with inhibition of
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